CANY
YMAB

Caxton Associates (New York)’s Y-mAbs Therapeutics YMAB Stock Holding History

Caxton Associates (New York)’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,807
Closed -$306K – 615
2024
Q1 		$306K Buy
+18,807
New +$253K 0.02% 384
2023
Q2 		– Sell
-43,046
Closed -$216K – 671
2023
Q1 		$216K Buy
+43,046
New +$176K 0.03% 407

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Caxton Associates (New York)'s YMAB Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 18,807 shares — an estimated $306K sold.

Caxton Associates (New York) first reported a position in YMAB in Q1 2023 and held it in 2 quarters. The position peaked at $306K in Q1 2024. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,807 Y-mAbs Therapeutics shares in Q2 2024, an estimated $306K.
  • Caxton Associates (New York) first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 2 quarters.
  • Caxton Associates (New York)'s Y-mAbs Therapeutics position peaked at $306K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.